[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 27 of about 27
1. Nakamura R, Saikawa Y, Kubota T, Kumagai A, Kiyota T, Ohashi M, Yoshida M, Otani Y, Kumai K, Kitajima M: Role of the MTT chemosensitivity test in the prognosis of gastric cancer patients after postoperative adjuvant chemotherapy. Anticancer Res; 2006 Mar-Apr;26(2B):1433-7
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of the MTT chemosensitivity test in the prognosis of gastric cancer patients after postoperative adjuvant chemotherapy.
  • MTTA) in the selection of anticancer drugs against advanced gastric cancer (AGC) was evaluated.
  • MTTA is widely used to predict patient responses to particular drugs, allowing for the selection of appropriate chemotherapeutic drugs and the avoidance of ineffective chemotherapeutic drugs, thereby improving patient survival.
  • In this study, the present clinical roles of MTTA and the data from 202 patients with stage III or IV gastric cancer analyzed for survival outcome following surgery, with or without postoperative chemotherapy, evaluated by MTTA, are discussed.
  • The patients were divided into 3 groups; an adapted group found to be sensitive to chemotherapy by MTTA, a non-adapted group found to be insensitive to chemotherapy by MTTA and a group that received no chemotherapy.
  • For stage III gastric cancer patients, the adapted group had a statistically better survival rate compared to the other groups, while for stage IV patients, there was no difference in survival rate between any of the groups.
  • However, further classification of stage IV patients as to the presence or absence of peritoneal dissemination (P) showed that the adapted group with P showed better prognoses than the other groups with P.
  • In conclusion, MTTA results predicted patient prognoses, based on the selection of appropriate chemotherapy.
  • [MeSH-major] Drug Screening Assays, Antitumor. Stomach Neoplasms / drug therapy. Tetrazolium Salts. Thiazoles
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Cohort Studies. Doxorubicin / administration & dosage. Female. Fluorouracil / administration & dosage. Humans. Male. Middle Aged. Neoplasm Staging. Paclitaxel / administration & dosage. Prognosis. Retrospective Studies. Taxoids / administration & dosage

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. METHYLTHIAZOLETETRAZOLIUM .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16619555.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Taxoids; 0 / Tetrazolium Salts; 0 / Thiazoles; 15H5577CQD / docetaxel; 298-93-1 / thiazolyl blue; 80168379AG / Doxorubicin; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


2. Bresciani C, Gama-Rodrigues J, Strassmann V, Waitzberg DL, Matsuda M, Pinotti HW: Long term (five-year) survival following radical surgical treatment plus adjuvant chemotherapy (FAM) in advanced gastric cancer: a controlled study. Rev Hosp Clin Fac Med Sao Paulo; 2000 Jul-Aug;55(4):129-36
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long term (five-year) survival following radical surgical treatment plus adjuvant chemotherapy (FAM) in advanced gastric cancer: a controlled study.
  • Several drugs and their associations are being used for adjuvant or complementary chemotherapy with the aim of improving results of gastric cancer treatment.
  • The objective of this study was to verify the impact of these drugs on nutrition and on survival rate after radical treatment of 53 patients with gastric cancer in stage III of the TNM classification.
  • In this latter group, chemotherapy toxicity in relation to hepatic, renal, cardiologic, neurological, hematologic, gastrointestinal, and dermatological functions was also studied.
  • There was no significant difference on admission between both groups in relation to gender, race, macroscopic tumoral type of tumor according to the Borrmann classification, location of the tumor in the stomach, length of the gastric resection, or response to cutaneous tests on delayed sensitivity.
  • Chemotherapy was started on average, 2.3 months following surgical treatment.
  • 2) There was no occurrence of cardiac, renal, neurological, or hepatic toxicity or death due to the chemotherapeutic method per se;.
  • 5) Therefore, we concluded, after a 5-year follow-up, chemotherapy with the FAM regimen did not increase the survival rate.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Stomach Neoplasms / surgery
  • [MeSH-minor] Case-Control Studies. Chemotherapy, Adjuvant. Disease-Free Survival. Doxorubicin / administration & dosage. Female. Fluorouracil / administration & dosage. Follow-Up Studies. Humans. Male. Middle Aged. Mitomycin / administration & dosage. Neoplasm Staging. Nutritional Status / drug effects. Recurrence. Survival Rate

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11082221.001).
  • [ISSN] 0041-8781
  • [Journal-full-title] Revista do Hospital das Clínicas
  • [ISO-abbreviation] Rev Hosp Clin Fac Med Sao Paulo
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial
  • [Publication-country] Brazil
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; 80168379AG / Doxorubicin; U3P01618RT / Fluorouracil; FAM protocol
  •  go-up   go-down


3. Lee JJ, Kim SY, Shin IS, Cho KS, Joo HZ, Yoon C, Kim YW, Yoon HJ: Randomized phase III trial of cisplatin, epirubicin, leucovorin, 5-fluorouracil (PELF) combination versus 5-fluorouracil alone as adjuvant chemotherapy in curative resected stage III gastric cancer. Cancer Res Treat; 2004 Apr;36(2):140-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Randomized phase III trial of cisplatin, epirubicin, leucovorin, 5-fluorouracil (PELF) combination versus 5-fluorouracil alone as adjuvant chemotherapy in curative resected stage III gastric cancer.
  • PURPOSE: The combination of cisplatin, epirubicin, leucovorin and 5-fluorouracil (PELF) administration, as adjuvant chemotherapy after curative resection for gastric cancer, was compared with 5-fluorouracil (5-FU) administration alone.
  • METHODS: From August 1996 to July 1999, 54 patients were selected subsequent to being diagnosed with stage III cancer after a curative resection for gastric cancer.
  • The patients were stratified according to stage IIIA/IIIB and subtotal/total gastrectomy, and then they were randomized into each treatment group, i.e. the PELF or 5-FU alone groups.
  • CONCLUSIONS: This study showed that the PELF combination, as an adjuvant therapy for gastric cancer after a curative resection, was a less effective treatment, and it had more toxic effects than the 5-FU.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1999 Jan;17(1):319-23 [10458249.001]
  • [Cites] Eur J Cancer. 1999 Jul;35(7):1059-64 [10533448.001]
  • [Cites] Ann Oncol. 1997 Feb;8(2):163-8 [9093725.001]
  • [Cites] Ann Surg Oncol. 1995 Nov;2(6):488-94 [8591078.001]
  • [Cites] Br J Cancer. 1996 Feb;73(4):549-52 [8595173.001]
  • [Cites] J Surg Oncol. 1994 Sep;57(1):40-5 [8065152.001]
  • [Cites] J Clin Oncol. 1994 Dec;12(12):2687-93 [7989945.001]
  • [Cites] Eur J Cancer. 1993;29A(3):340-2 [8398330.001]
  • [Cites] J Clin Oncol. 1993 Aug;11(8):1441-7 [8336183.001]
  • [Cites] Ann Oncol. 1991 Mar;2(3):229-30 [2043494.001]
  • [Cites] J Clin Oncol. 1990 Aug;8(8):1362-9 [2199622.001]
  • [Cites] World J Surg. 1984 Jun;8(3):308-14 [6464487.001]
  • [Cites] World J Surg. 1977 Mar;2(1):213-21 [868069.001]
  • [Cites] Cancer. 1974 Nov;34(5):1576-86 [4279136.001]
  • [Cites] Int Surg. 2000 Jul-Sep;85(3):209-15 [11324997.001]
  • [Cites] Ann Surg Oncol. 2000 Apr;7(3):210-7 [10791852.001]
  • [Cites] J Clin Oncol. 1999 Dec;17(12):3810-5 [10577853.001]
  • [Cites] Am J Clin Oncol. 1999 Dec;22(6):580-6 [10597742.001]
  • [Cites] N Engl J Med. 1999 Mar 25;340(12):908-14 [10089184.001]
  • (PMID = 20396554.001).
  • [ISSN] 2005-9256
  • [Journal-full-title] Cancer research and treatment : official journal of Korean Cancer Association
  • [ISO-abbreviation] Cancer Res Treat
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2855100
  • [Keywords] NOTNLM ; 5-Fluorouracil / Adjuvant chemotherapy / Cisplatin / Epirubicin / Leucovorin / Phase III trial / Stomach neoplasm
  •  go-up   go-down


Advertisement
4. Ojima H, Araki K, Kato T, Okamura K, Manda R, Hirayama I, Hosouchi Y, Nishida Y, Kuwano H: Clinicopathological characteristics and outcome indicators of stage II gastric cancer according to the Japanese classification of gastric cancer. Anticancer Res; 2006 Mar-Apr;26(2B):1385-90
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathological characteristics and outcome indicators of stage II gastric cancer according to the Japanese classification of gastric cancer.
  • BACKGROUND: The characteristics of stage II gastric cancer according to the Japanese Classification of Gastric Cancer (JCGC) were examined and the high-risk factors predicting poor prognosis were detected.
  • PATIENTS AND METHODS: In total, 107 patients, who underwent clinically curative gastrectomy with D2 lymphadenectomy for stage II gastric cancer, were included.
  • Survival curves of the depth of invasion, lymph node metastasis, the ratio of involved: resected lymph nodes and chemotherapy treatment were compared.
  • Survival rates with adjuvant chemotherapy were slightly higher than without adjuvant chemotherapy, but the difference was not significant.
  • CONCLUSION: pT2pN1 (stage II) gastric cancers according to the JCGC, especially pSSpN1 cases, included stage IIIB and IV gastric cancers according to the International Union Against Cancer / American Joint Committee on Cancer (UICC/AJCC); therefore, the prognosis of these might be poor.
  • With pSSpN1 cases, according to the JCGC, anticancer chemotherapy equivalent to that required for stage III gastric cancer cases is necessary.
  • [MeSH-major] Stomach Neoplasms / classification. Stomach Neoplasms / pathology
  • [MeSH-minor] Aged. Chemotherapy, Adjuvant. Disease-Free Survival. Female. Gastrectomy. Humans. Lymph Node Excision. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Recurrence, Local / pathology. Neoplasm Staging. Risk Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16619548.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


5. Chen CN, Cheng YM, Lin MT, Hsieh FJ, Lee PH, Chang KJ: Association of color Doppler vascularity index and microvessel density with survival in patients with gastric cancer. Ann Surg; 2002 Apr;235(4):512-8
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of color Doppler vascularity index and microvessel density with survival in patients with gastric cancer.
  • OBJECTIVE: The purpose of this study was to investigate the clinical usefulness of microvessel density (MVD) and an in vivo angiogenesis parameter, color Doppler vascularity index (CDVI), in patients with gastric cancer.
  • All these studies were accomplished on tissue sections retrospectively obtained from surgical specimens.
  • However, an in vivo method to assess tumor angiogenesis for human malignancies is highly desirable for diagnostic purpose, treatment planning, and follow-up.
  • The CDVI is a new ultrasound parameter for evaluating in vivo angiogenesis, has a good correlation with status of lymph node metastasis in cervical carcinoma, and can predict distant metastasis and survival in colon cancer patients.
  • Therefore, the CDVI may also be useful to assess in vivo angiogenesis in human gastric cancer.
  • METHODS: A total of 79 patients with gastric cancer were enrolled in this study, and microvessel density was evaluated by using immunohistochemical staining of surgical specimens with anti-CD-34 antibody.
  • In addition to vascular invasion, the CDVI was another independent prognostic factor in the patients with stage III gastric cancer.
  • CONCLUSIONS: Vascular invasion was an important prognostic indicator in gastric cancer.
  • The high CDVI was a good preoperative indicator of early death in stage III gastric cancer patients.
  • Thus, the CDVI may be helpful in selecting patients with gastric cancer for neoadjuvant chemotherapy and/or anti-angiogenic therapy.
  • [MeSH-major] Adenocarcinoma / blood supply. Adenocarcinoma / mortality. Neovascularization, Pathologic / ultrasonography. Stomach Neoplasms / blood supply. Stomach Neoplasms / mortality. Ultrasonography, Doppler, Color / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Microcirculation / pathology. Microcirculation / ultrasonography. Middle Aged. Neoplasm Invasiveness. Prognosis. Regression Analysis. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1996 Jul 15;78(2):226-31 [8673996.001]
  • [Cites] Cancer. 1963 Apr;16:453-67 [13958548.001]
  • [Cites] Br J Cancer. 1996 Sep;74(5):766-72 [8795580.001]
  • [Cites] J Immunol. 1997 Feb 1;158(3):1302-9 [9013973.001]
  • [Cites] Cancer. 1998 May 15;82(10):1881-6 [9587120.001]
  • [Cites] Cancer. 1998 Sep 15;83(6):1189-96 [9740085.001]
  • [Cites] Invest Radiol. 1999 Mar;34(3):194-8 [10084663.001]
  • [Cites] Cancer. 1999 Feb 1;85(3):651-7 [10091738.001]
  • [Cites] Am J Pathol. 2000 Feb;156(2):361-81 [10666364.001]
  • [Cites] Carcinogenesis. 2000 Mar;21(3):505-15 [10688871.001]
  • [Cites] Pharmacol Rev. 2000 Jun;52(2):237-68 [10835101.001]
  • [Cites] Cancer Res. 2000 Jun 1;60(11):2892-7 [10850434.001]
  • [Cites] Eur J Cancer. 1973 Mar;9(3):223-7 [4787857.001]
  • [Cites] Cancer Res. 1974 May;34(5):997-1004 [4841969.001]
  • [Cites] Cancer Res. 1976 Mar;36(3):889-94 [1253177.001]
  • [Cites] Radiology. 1979 Dec;133(3 Pt 1):677-80 [504647.001]
  • [Cites] AJR Am J Roentgenol. 1981 Nov;137(5):969-72 [6975024.001]
  • [Cites] J Natl Cancer Inst. 1983 Aug;71(2):275-9 [6576187.001]
  • [Cites] Radiology. 1988 Jan;166(1 Pt 1):57-62 [2447604.001]
  • [Cites] Gastrointest Radiol. 1988 Jul;13(3):197-9 [3290033.001]
  • [Cites] Arch Surg. 1989 Mar;124(3):314-8 [2919965.001]
  • [Cites] J Natl Cancer Inst. 1990 Jan 3;82(1):4-6 [1688381.001]
  • [Cites] Nature. 1990 Dec 6;348(6301):555-7 [1701033.001]
  • [Cites] N Engl J Med. 1991 Jan 3;324(1):1-8 [1701519.001]
  • [Cites] Cell. 1991 Jan 25;64(2):327-36 [1703045.001]
  • [Cites] Eur J Cancer. 1991;27(6):781-5 [1712608.001]
  • [Cites] Int J Cancer. 1991 Sep 9;49(2):203-7 [1879965.001]
  • [Cites] Radiology. 1991 Oct;181(1):241-4 [1887039.001]
  • [Cites] Lancet. 1992 Jul 18;340(8812):145-6 [1378165.001]
  • [Cites] J Natl Cancer Inst. 1992 Dec 16;84(24):1875-87 [1281237.001]
  • [Cites] Am J Pathol. 1993 Aug;143(2):401-9 [7688183.001]
  • [Cites] Int J Cancer. 1993 Sep 30;55(3):371-4 [7690738.001]
  • [Cites] J Natl Cancer Inst. 1993 Nov 17;85(22):1839-44 [8230264.001]
  • [Cites] Int J Cancer. 1993 Nov 11;55(5):739-44 [8244569.001]
  • [Cites] Cancer. 1994 Feb 15;73(4):1251-6 [7508817.001]
  • [Cites] Dis Colon Rectum. 1994 Sep;37(9):921-6 [7521279.001]
  • [Cites] Science. 1994 Sep 9;265(5178):1582-4 [7521539.001]
  • [Cites] Blood. 1994 Oct 1;84(7):2068-101 [7522621.001]
  • [Cites] Ann Oncol. 1994 Sep;5(7):609-16 [7993836.001]
  • [Cites] J Clin Oncol. 1995 Feb;13(2):477-81 [7531224.001]
  • [Cites] Radiology. 1995 Apr;195(1):86-90 [7534429.001]
  • [Cites] Cancer Res. 1995 Oct 15;55(20):4575-80 [7553632.001]
  • [Cites] Cancer Res. 1995 Nov 1;55(21):5049-53 [7585550.001]
  • [Cites] Nat Med. 1995 Jan;1(1):27-31 [7584949.001]
  • [Cites] Ann Surg. 1995 Dec;222(6):695-9 [8526575.001]
  • [Cites] Cancer Res. 1996 Jun 1;56(11):2671-6 [8653715.001]
  • [Cites] Br J Cancer. 1999 Mar;79(7-8):1255-61 [10098768.001]
  • [Cites] J Ultrasound Med. 1999 Aug;18(8):547-51 [10447080.001]
  • [Cites] Cancer Res. 1996 Aug 1;56(15):3436-40 [8758908.001]
  • (PMID = 11923607.001).
  • [ISSN] 0003-4932
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC1422466
  •  go-up   go-down


6. Oh SY, Lee SJ, Lee J, Lee S, Kim SH, Kwon HC, Lee GW, Kang JH, Hwang IG, Jang JS, Lim HY, Park YS, Kang WK, Kim HJ: Gastric leptomeningeal carcinomatosis: multi-center retrospective analysis of 54 cases. World J Gastroenterol; 2009 Oct 28;15(40):5086-90
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gastric leptomeningeal carcinomatosis: multi-center retrospective analysis of 54 cases.
  • AIM: To identify the clinical features and outcomes of infrequently reported leptomeningeal carcinomatosis (LMC) of gastric cancer.
  • METHODS: We analyzed 54 cases of cytologically confirmed gastric LMC at four institutions from 1994 to 2007.
  • The majority of patients had advanced disease at initial diagnosis of gastric cancer.
  • The clinical or pathologic tumor, node and metastasis stage of the primary gastric cancer was IV in 38 patients (70%).
  • The median interval from diagnosis of the primary malignancy to the diagnosis of LMC was 6.3 mo, ranging between 0 and 73.1 mo.
  • Of the initial endoscopic findings for the 45 available patients, 23 (51%) of the patients were Bormann type III and 15 (33%) patients were Bormann type IV.
  • Intrathecal (IT) chemotherapy was administered to 36 patients-primarily methotrexate alone (61%), but also in combination with hydrocortisone/+/- Ara-C (39%).
  • The median number of IT treatments was 7 (range, 1-18).
  • Concomitant radiotherapy was administered to 18 patients, and concomitant chemotherapy to seven patients.
  • In the univariate analysis of survival duration, hemoglobin, IT chemotherapy, and cytological negative conversion showed superior survival duration (P = 0.038, P = 0.010, and P = 0.002, respectively).
  • CONCLUSION: Although these patients had a fatal clinical course, cytologic negative conversion by IT chemotherapy may improve survival.
  • [MeSH-major] Meningeal Carcinomatosis / diagnosis. Stomach Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy / methods. Endoscopy / methods. Female. Humans. Male. Middle Aged. Retrospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg Oncol. 1999 Dec;6(8):771-6 [10622506.001]
  • [Cites] Surg Today. 2000;30(6):485-90 [10883456.001]
  • [Cites] Jpn J Clin Oncol. 2003 Dec;33(12):608-12 [14769837.001]
  • [Cites] J Neurooncol. 2004 Jan;66(1-2):167-74 [15015782.001]
  • [Cites] N Engl J Med. 1973 Oct 11;289(15):770-3 [4517004.001]
  • [Cites] Cancer. 1982 Feb 15;49(4):759-72 [6895713.001]
  • [Cites] Surgery. 1990 Feb;107(2):140-8 [1689080.001]
  • [Cites] Cancer. 1992 Sep 15;70(6):1462-6 [1515997.001]
  • [Cites] Arch Neurol. 1994 May;51(5):457-61 [8179494.001]
  • [Cites] J Neurooncol. 1998 Jun-Jul;38(2-3):245-52 [9696379.001]
  • [Cites] Cancer Treat Rev. 1999 Apr;25(2):103-19 [10395835.001]
  • [Cites] J Neurooncol. 1999 May;43(1):59-62 [10448872.001]
  • [Cites] Cancer Invest. 2005;23(2):145-54 [15813508.001]
  • [Cites] Expert Opin Pharmacother. 2005 Jun;6(7):1115-25 [15957966.001]
  • [Cites] J Natl Compr Canc Netw. 2005 Sep;3(5):693-703 [16194457.001]
  • [Cites] Cancer Treat Res. 2005;125:31-52 [16211882.001]
  • [Cites] Cancer Treat Res. 2005;125:147-58 [16211888.001]
  • [Cites] Curr Opin Oncol. 2006 Nov;18(6):637-43 [16988587.001]
  • [Cites] Clin J Oncol Nurs. 2008 Jun;12(3):429-35 [18515241.001]
  • (PMID = 19860003.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC2768889
  •  go-up   go-down


7. Ho CL, Hsieh AT, Dai MS, Chen YC, Kao WY, Chao TY: Non-Hodgkin's lymphoma of the stomach: treatment outcomes for 57 patients over a 20-year period. J Chin Med Assoc; 2005 Jan;68(1):11-5
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-Hodgkin's lymphoma of the stomach: treatment outcomes for 57 patients over a 20-year period.
  • BACKGROUND: Gastric non-Hodgkin's lymphoma (NHL) is a rare subtype of malignancy, for which no consensus exists about treatment.
  • In this study, the treatment outcomes of gastric NHL in 57 patients were retrospectively evaluated for a period of 20 years at a single institute.
  • METHODS: Clinical stages were classified according to the Ann Arbor staging system: 29 patients were stage 1, 17 stage II, two stage III, and nine stage IV.
  • The 46 stage I/II patients received aggressive, multimodal therapy: 24 of these (group A) were treated with surgery-based management, which included surgery alone (n = 6), surgery + chemotherapy (CT; n = 14), surgery + radiotherapy (RT; n = 2), and surgery + CT + RT (n = 2); 22 patients (group B) did not receive surgery, but received CT alone (n = 11), CT + RT (n = 5), or, in patients with low-grade mucosa-associated lymphoid tissue (MALT) lymphoma, an oral anti-Helicobacter pylori regimen (n = 6).
  • The 11 stage III/IV patients received CT and/or RT with regimens similar to those for stage I/III patients.
  • RESULTS: Except for 1 patient with an initial surgical diagnosis, 56 patients underwent gastric endoscopic examination, which proved that 42 had NHL.
  • After multimodal treatment (n = 46) and a median follow-up of 54 months (range, 1-210 months), the 5-year survival rate was 40.3%.
  • The 5-year survival rates for stage 1, II and III/IV patients were 57.2%, 47% and 0%, respectively (p < 0.005).
  • Of the 22 non-surgical patients (group B) who received CT, alone or combined with RT, 14 remained disease-free after a median follow-up of 40 months (range, 4-189 months); 1 patient died because of massive gastric hemorrhage after CT.
  • All stage III and IV patients died after a median survival of 4 months (range, 1-8 months).
  • CONCLUSION: Clinical stage is the most important factor predicting the long-term survival of patients with gastric NHL.
  • In early-stage gastric NHL, non-surgical treatment seems able to achieve the aims of improved long-term survival and, in some instances, cure.
  • [MeSH-major] Lymphoma, Non-Hodgkin / therapy. Stomach Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Stomach / pathology. Survival Analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15742857.001).
  • [ISSN] 1726-4901
  • [Journal-full-title] Journal of the Chinese Medical Association : JCMA
  • [ISO-abbreviation] J Chin Med Assoc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China (Republic : 1949- )
  •  go-up   go-down


8. Ott K, Lordick F, Herrmann K, Krause BJ, Schuhmacher C, Siewert JR: The new credo: induction chemotherapy in locally advanced gastric cancer: consequences for surgical strategies. Gastric Cancer; 2008;11(1):1-9
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The new credo: induction chemotherapy in locally advanced gastric cancer: consequences for surgical strategies.
  • Perioperative chemotherapy in stage II and stage III gastric cancer is now accepted as a standard of care in the Western world.
  • Two randomized phase III studies have shown improved survival for patients with induction chemotherapy followed by surgery compared with surgery alone.
  • It is generally accepted that patients who respond to induction therapy have a significantly improved survival compared with that in nonresponding patients.
  • In adenocarcinomas of the esophagogastric junction (AEG), fluorodeoxyglucose-positron emission tomography (FDG-PET) prospectively was established as a surrogate predicting response and prognosis.
  • The MUNICON (Metabolic response evalUatioN for Individualisation of neoadjuvant Chemotherapy in oesOphageal and oesophagogastric adeNocarcinoma) I study confirmed prospectively the usefulness of early metabolic response evaluation and showed the feasibility of a PET-guided treatment algorithm.
  • These findings are an important step forward in the tailoring of multimodal treatment in accordance with tumor biology.
  • In gastric cancer, we have analyzed FDG-PET in a prospective study.
  • In gastric cancer the issue is more complicated, because about 30% of gastric cancers cannot be visualized with sufficient contrast for quantification.
  • Insufficient FDG uptake is mostly associated with diffuse-type gastric cancer with signet ring cells and mucinous content.
  • Treatment concepts such as immediate resection after only 2 weeks of induction therapy with or without adjuvant treatment could be considered in metabolic nonresponders, or modified chemotherapy regimens, possibly including biologically targeted drugs, could be considered in those with FDG-nonavid tumors.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Neoadjuvant Therapy / methods. Positron-Emission Tomography. Stomach Neoplasms / drug therapy. Stomach Neoplasms / surgery
  • [MeSH-minor] Contrast Media. Disease Progression. Fluorodeoxyglucose F18. Humans. Neoplasm Staging. Prognosis. Radiopharmaceuticals. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1999 Mar 25;340(12):908-14 [10089184.001]
  • [Cites] Cancer. 2005 Dec 1;104(11):2365-72 [16245310.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92 (3):205-16 [10655437.001]
  • [Cites] Ann Surg. 2007 Oct;246(4):624-8; discussion 628-31 [17893499.001]
  • [Cites] J Clin Oncol. 1999 Aug;17 (8):2403-11 [10561303.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2006 Feb;33(2):148-55 [16228236.001]
  • [Cites] Cancer. 2003 Oct 1;98(7):1521-30 [14508841.001]
  • [Cites] Cancer. 2001 Jul 15;92(2):279-86 [11466680.001]
  • [Cites] Radiology. 2006 May;239(2):472-80 [16543584.001]
  • [Cites] J Clin Oncol. 2001 Jun 15;19(12 ):3058-65 [11408502.001]
  • [Cites] J Nucl Med. 2005 Dec;46(12 ):2029-34 [16330567.001]
  • [Cites] Ann Surg. 1999 Mar;229(3):303-8 [10077040.001]
  • [Cites] Cancer. 1993 Oct 1;72(7):2089-97 [8374867.001]
  • [Cites] Lancet Oncol. 2007 Sep;8(9):797-805 [17693134.001]
  • [Cites] Gastric Cancer. 2003;6(3):159-67 [14520529.001]
  • [Cites] Surg Oncol Clin N Am. 2000 Jan;9(1):97-117, vii-viii [10601527.001]
  • [Cites] J Clin Oncol. 2006 Oct 10;24(29):4692-8 [16966684.001]
  • [Cites] Clin Cancer Res. 2003 Jun;9(6):2307-15 [12796400.001]
  • [Cites] J Clin Oncol. 2004 Jun 1;22(11):2069-77 [15082726.001]
  • [Cites] J Clin Oncol. 2003 Dec 15;21(24):4604-10 [14673049.001]
  • [Cites] J Nucl Med. 2005 Oct;46(10 ):1582-8 [16204706.001]
  • [Cites] Ann Surg. 2005 May;241(5):810-7; discussion 817-20 [15849517.001]
  • [Cites] Jpn J Clin Oncol. 2003 Oct;33(10):533-7 [14623923.001]
  • [Cites] Gastric Cancer. 2000 Dec 27;3(3):128-133 [11984725.001]
  • [Cites] Zhonghua Wai Ke Za Zhi. 2006 May 15;44(10 ):661-4 [16784672.001]
  • [Cites] Nucl Med Commun. 2004 Aug;25(8):825-31 [15266178.001]
  • [Cites] World J Surg. 2004 Mar;28(3):247-53 [14961197.001]
  • [Cites] Gastric Cancer. 2006;9(3):192-6 [16952037.001]
  • [Cites] Ann Thorac Surg. 2004 Oct;78(4):1152-60; discussion 1152-60 [15464463.001]
  • [Cites] Cancer. 2005 Jun 1;103(11):2383-90 [15856477.001]
  • [Cites] Cancer. 1981 Jan 1;47(1):207-14 [7459811.001]
  • [Cites] Gan To Kagaku Ryoho. 2000 Dec;27(14):2179-84 [11142160.001]
  • [Cites] Cancer. 1994 Jun 1;73(11):2680-6 [8194005.001]
  • [Cites] Cancer Chemother Pharmacol. 2007 Feb;59(3):313-20 [16770582.001]
  • [Cites] Cancer. 2001 Mar 1;91(5):918-27 [11251943.001]
  • [Cites] Ann Surg Oncol. 2001 Jul;8(6):519-24 [11456051.001]
  • [Cites] Br J Cancer. 2006 May 8;94(9):1281-6 [16622464.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2003 Feb;30(2):288-95 [12552348.001]
  • [Cites] N Engl J Med. 2006 Jul 6;355(1):11-20 [16822992.001]
  • (PMID = 18373171.001).
  • [ISSN] 1436-3291
  • [Journal-full-title] Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  • [ISO-abbreviation] Gastric Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Contrast Media; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  • [Number-of-references] 42
  •  go-up   go-down


9. Kochi M, Fujii M, Kanamori N, Kaiga T, Takahashi T, Kobayashi M, Takayama T: Neoadjuvant chemotherapy with S-1 and CDDP in advanced gastric cancer. J Cancer Res Clin Oncol; 2006 Dec;132(12):781-5
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neoadjuvant chemotherapy with S-1 and CDDP in advanced gastric cancer.
  • PURPOSE: This retrospective study evaluated the effects of neoadjuvant chemotherapy in advanced gastric cancer.
  • METHODS: Between 2002 and 2005, we treated 14 patients with advanced gastric cancer (involvement of more than five nodes or tumor invasion into pancreas) and 25 patients with Stage III gastric cancer.
  • The group of 14 patients with advanced gastric cancer received combination chemotherapy with S-1 and cis-diamminedichloroplatinum (CDDP) as a neoadjuvant chemotherapy (NAC).
  • The 25 patients with Stage III gastric cancer was carried surgery alone (SA).
  • RESULTS: All patients of NAC group completed the planned regimens of chemotherapy and surgery.
  • CONCLUSION: Neoadjuvant chemotherapy with TS-1 + CDDP improves the survival in patients with advanced gastric cancer.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / administration & dosage. Oxonic Acid / administration & dosage. Stomach Neoplasms / drug therapy. Tegafur / administration & dosage
  • [MeSH-minor] Aged. Aged, 80 and over. Disease Progression. Drug Administration Schedule. Drug Combinations. Female. Humans. Male. Middle Aged. Neoadjuvant Therapy / adverse effects. Neoplasm Staging. Retrospective Studies. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 2004 May 17;90(10):1888-92 [15138467.001]
  • [Cites] Br J Cancer. 2004 May 4;90(9):1727-32 [15150592.001]
  • [Cites] N Engl J Med. 1999 Mar 25;340(12):908-14 [10089184.001]
  • [Cites] Oncology. 2004;67(1):48-53 [15459495.001]
  • [Cites] World J Surg. 2002 Sep;26(9):1155-9 [12209246.001]
  • [Cites] J Clin Oncol. 1996 Jun;14 (6):1818-28 [8656250.001]
  • [Cites] Br J Surg. 2005 Sep;92(9):1103-9 [16106493.001]
  • [Cites] J Clin Oncol. 2005 Oct 1;23(28):6957-65 [16145066.001]
  • [Cites] Oncology. 2004;66(6):445-9 [15452373.001]
  • [Cites] Eur J Cancer. 1998 Oct;34(11):1715-20 [9893658.001]
  • [Cites] Br J Cancer. 2003 Dec 15;89(12):2207-12 [14676796.001]
  • [Cites] Eur J Cancer. 1994;30A(9):1269-75 [7999411.001]
  • [Cites] Lancet. 1999 Jul 24;354(9175):273-7 [10440302.001]
  • [Cites] J Gastrointest Surg. 2002 Mar-Apr;6(2):212-23; discussion 223 [11992807.001]
  • (PMID = 16804723.001).
  • [ISSN] 0171-5216
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


10. Papadakou M, Xydakis E, Bonios M, Makropoulou E, Boukis C, Kakavoulis T, Karaliotas C, Panagos G: Adjuvant chemotherapy with cisplatin, etoposide, fluorouracil and leucovorin for gastric carcinoma. J BUON; 2006 Jul-Sep;11(3):285-9
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant chemotherapy with cisplatin, etoposide, fluorouracil and leucovorin for gastric carcinoma.
  • CEFL) combination chemotherapy given as adjuvant treatment to patients with stage III gastric cancer.
  • PATIENTS AND METHODS: A total of 33 patients who had undergone curative resection for stage III gastric adenocarcinoma were enrolled in our adjuvant chemotherapy protocol to receive 6 cycles of CEFL starting within 8 weeks from surgery.
  • RESULTS: Treatment was completed by 30 (91%) patients.
  • Patients with stage IIIA disease had longer RFS that those with stage IIIB (37 vs. 25 months, p>0.05).
  • Mean OS was 35 months (range 4 to 114+), while stage IIIA patients survived longer than IIIB ones (42 vs. 27 months, p>0.05).
  • Principal side effects of therapy were from the bone marrow and the gastrointestinal tract.
  • There were 2 treatment-related deaths due to neutropenic sepsis.
  • CONCLUSION: CEFL regimen appears to be an effective adjuvant treatment for patients with stage III gastric carcinoma as it prolongs both RFS and OS.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Disease-Free Survival. Etoposide / administration & dosage. Female. Fluorouracil / administration & dosage. Humans. Leucovorin / administration & dosage. Male. Middle Aged. Survival Rate

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17309151.001).
  • [ISSN] 1107-0625
  • [Journal-full-title] Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  • [ISO-abbreviation] J BUON
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


11. Cho MY, Joh YG, Kim NR, Jung SI, Bae JW, Kim YC, Koo BH, Whang CW, Suh SO: T-lymphocyte subsets in patients with AJCC stage III gastric cancer during postoperative adjuvant chemotherapy. American Joint Committee on Cancer. Scand J Surg; 2002;91(2):172-7
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] T-lymphocyte subsets in patients with AJCC stage III gastric cancer during postoperative adjuvant chemotherapy. American Joint Committee on Cancer.
  • BACKGROUND AND AIMS: Advanced neoplastic diseases alter the immune response in cancer patients.
  • The aim of this study was to evaluate the changes of T-lymphocyte subsets during postoperative adjuvant chemotherapy, and the relationship between T-lymphocyte subsets and tumor recurrence in AJCC stage III gastric cancers.
  • MATERIAL AND METHODS: Analysis of T-lymphocyte subsets was performed in 39 patients with stage III gastric adenocarcinoma who had undergone a curative gastric resection and postoperative chemotherapy.
  • RESULTS: The 5-year disease-free survival rates of patients with stage 3a and 3b gastric cancer were 57.1% and 33.3%, respectively (p = 0.06).
  • However, most values of the T-lymphocyte subsets showed no statistically significant difference when comparing the stage 3a and 3b disease patient groups.
  • CONCLUSIONS: The results of this study suggest that immunosuppression associated with CD3+ and CD4+ T-cell depression is a risk factor for postoperative recurrence in patients with stage III gastric cancer.
  • [MeSH-major] Adenocarcinoma / immunology. Stomach Neoplasms / immunology. T-Lymphocyte Subsets
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Analysis of Variance. Antibodies, Monoclonal. Chemotherapy, Adjuvant. Disease-Free Survival. Female. Flow Cytometry. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Prospective Studies. Risk Factors. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12164518.001).
  • [ISSN] 1457-4969
  • [Journal-full-title] Scandinavian journal of surgery : SJS : official organ for the Finnish Surgical Society and the Scandinavian Surgical Society
  • [ISO-abbreviation] Scand J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal
  •  go-up   go-down


12. Kubota T, Egawa T, Otani Y, Furukawa T, Saikawa Y, Yoshida M, Watanabe M, Kumai K, Kitajima M: Cancer chemotherapy chemosensitivity testing is useful in evaluating the appropriate adjuvant cancer chemotherapy for stages III/IV gastric cancers without peritoneal dissemination. Anticancer Res; 2003 Jan-Feb;23(1B):583-7
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cancer chemotherapy chemosensitivity testing is useful in evaluating the appropriate adjuvant cancer chemotherapy for stages III/IV gastric cancers without peritoneal dissemination.
  • BACKGROUND: Because of the low chemosensitivity of gastric cancer to conventional antitumor agents, the role of adjuvant chemotherapy for patients with advanced gastric cancer is controversial.
  • We have previously proposed the necessity to evaluate the appropriateness of particular adjuvant cancer chemotherapies in individual advanced gastric cancer patients using chemosensitivity testing.
  • In the present study, we compared the chemosensitivity and clinical outcomes of patients with Stages III and IV gastric cancer.
  • PATIENTS AND METHODS: A total of 282 patients with advanced gastric cancer were analyzed retrospectively in terms of chemosensitivity as detected by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay and survival outcome after surgery.
  • Patients were split into groups according to Stage III or IV gastric cancer, then categorized into those that received surgery without chemotherapy (surgery-alone), and those that received adjuvant chemotherapy, for which all the evaluable cases were further divided into sensitive and resistant cases as determined by MTT assay.
  • RESULTS: For Stage III gastric cancer patients, the sensitive group had a more favorable survival outcome than the other two groups.
  • For Stage IV gastric cancer patients, the sensitive groups, had a more favorable survival outcome than the other two groups, but only in the absence of peritoneal dissemination.
  • CONCLUSION: Chemosensitivity testing, based on the MTT assay, was useful in evaluating the appropriate cancer chemotherapy for patients with Stages III/IV gastric cancer without peritoneal dissemination.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Stomach Neoplasms / drug therapy. Stomach Neoplasms / pathology
  • [MeSH-minor] Aged. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Drug Screening Assays, Antitumor. Female. Fluorouracil / administration & dosage. Humans. Male. Middle Aged. Mitomycin / administration & dosage. Neoplasm Staging. Peritoneal Neoplasms / secondary. Retrospective Studies. Survival Rate. Tegafur / administration & dosage. Tetrazolium Salts. Thiazoles. Treatment Outcome. Uracil / administration & dosage

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. METHYLTHIAZOLETETRAZOLIUM .
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12680150.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Tetrazolium Salts; 0 / Thiazoles; 1548R74NSZ / Tegafur; 298-93-1 / thiazolyl blue; 50SG953SK6 / Mitomycin; 56HH86ZVCT / Uracil; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil; 1-UFT protocol
  •  go-up   go-down


13. Kodera Y, Ishiyama A, Yoshikawa T, Kinoshita T, Ito S, Yokoyama H, Mochizuki Y, Ito H, Tsuburaya A, Sakamoto J, Nakao A, Chubu Clinical Cancer Group: A feasibility study of postoperative chemotherapy with S-1 and cisplatin (CDDP) for gastric carcinoma (CCOG0703). Gastric Cancer; 2010 Aug;13(3):197-203
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A feasibility study of postoperative chemotherapy with S-1 and cisplatin (CDDP) for gastric carcinoma (CCOG0703).
  • BACKGROUND: The outcome of stage III gastric cancer patients treated by D2 dissection followed by adjuvant chemotherapy with S-1 remains unsatisfactory.
  • Moreover, some patients with a preoperative diagnosis of stage II/III turn out to be stage IV after surgical exploration, and a standard postoperative treatment for this population has not been established.
  • METHODS: A feasibility study of postoperative S-1/cisplatin (CDDP) was performed with patients who underwent gastrectomy for what turned out to be a stage IV gastric cancer.
  • The primary endpoint of the trial was the relative dose intensity during five courses of S-1/CDDP.
  • The median relative dose intensities of S-1 and CDDP were 37% and 40%, respectively.
  • Causes of treatment failure were failure to fulfill criteria for starting a new course within 5 weeks of the last administration of S-1 in 7, patient refusal in 6, disease recurrence/progression in 4, need to reduce dose by two levels in 4, and two successive skips of CDDP in 3 patients.
  • The median progression-free survival time of all patients was 363 days.
  • CONCLUSIONS: Although promising in the neoadjuvant and advanced/metastatic setting, S-1/CDDP is too toxic as a postgastrectomy treatment for Japanese patients.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Antineoplastic Agents / therapeutic use. Cisplatin / therapeutic use. Oxonic Acid / therapeutic use. Postoperative Care. Stomach Neoplasms / drug therapy. Tegafur / therapeutic use
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Disease Progression. Dose-Response Relationship, Drug. Drug Combinations. Feasibility Studies. Female. Gastrectomy. Humans. Japan. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Staging. Survival Analysis. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Oncol. 2010 May;21(5):1001-5 [19875759.001]
  • [Cites] N Engl J Med. 2008 Jan 3;358(1):36-46 [18172173.001]
  • [Cites] Gastric Cancer. 1998 Dec;1(1):25-30 [11957041.001]
  • [Cites] Gastric Cancer. 2006;9(2):129-35 [16767369.001]
  • [Cites] Lancet Oncol. 2008 Mar;9(3):215-21 [18282805.001]
  • [Cites] Gastric Cancer. 2004;7(2):104-9 [15224197.001]
  • [Cites] Gastric Cancer. 2008;11(4):192-3 [19132479.001]
  • [Cites] Gastric Cancer. 2006;9(2):51-66 [16767357.001]
  • [Cites] Am J Surg. 2004 Mar;187(3):440-5 [15006580.001]
  • [Cites] Gastric Cancer. 2007;10(2):129-34 [17577624.001]
  • [Cites] Clin Cancer Res. 2006 Jun 1;12(11 Pt 1):3402-7 [16740764.001]
  • [Cites] Oncology. 2007;73(1-2):65-71 [18334851.001]
  • [Cites] Gastric Cancer. 2007;10(1):29-34 [17334715.001]
  • [Cites] Oncology. 2000 Apr;58(3):191-7 [10765119.001]
  • [Cites] N Engl J Med. 2007 Nov 1;357(18):1810-20 [17978289.001]
  • [Cites] Eur J Cancer. 1998 Oct;34(11):1715-20 [9893658.001]
  • [Cites] Int J Cancer. 1999 Sep 24;83(1):18-29 [10449602.001]
  • [Cites] Br J Cancer. 2003 Dec 15;89(12):2207-12 [14676796.001]
  • [Cites] Jpn J Clin Oncol. 2008 Jul;38(7):504-6 [18617536.001]
  • [Cites] Oncology. 2008;74(1-2):37-41 [18544958.001]
  • [Cites] Eur J Surg Oncol. 2009 Nov;35(11):1158-63 [19328643.001]
  • [Cites] N Engl J Med. 2001 Sep 6;345(10):725-30 [11547741.001]
  • [Cites] Ann Oncol. 2005 Sep;16(9):1488-97 [15939717.001]
  • [Cites] J Cancer Res Clin Oncol. 2006 Dec;132(12):781-5 [16804723.001]
  • [Cites] N Engl J Med. 2006 Jul 6;355(1):11-20 [16822992.001]
  • (PMID = 20820990.001).
  • [ISSN] 1436-3305
  • [Journal-full-title] Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  • [ISO-abbreviation] Gastric Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


14. Suh SO, Kroh M, Kim NR, Joh YG, Cho MY: Effects of red ginseng upon postoperative immunity and survival in patients with stage III gastric cancer. Am J Chin Med; 2002;30(4):483-94
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of red ginseng upon postoperative immunity and survival in patients with stage III gastric cancer.
  • Meyer inhibits the recurrence of AJCC stage III gastric cancer and shows immunomodulatory activities during postoperative chemotherapy, after a curative resection with D2 lymph node dissection.
  • Flow cytometric analyses for peripheral T-lymphocyte subsets showed that the red ginseng powder restored CD4 levels to the initial preoperative values during postoperative chemotherapy.
  • Depression of CD3 during postoperative chemotherapy was also inhibited by the red ginseng powder ingestion.
  • This study demonstrated a five-year disease free survival and overall survival rate that was significantly higher in patients taking the red ginseng powder during postoperative chemotherapy versus control (68.2% versus 33.3%, 76.4% versus 38.5%, respectively, p < 0.05).
  • Additionally, red ginseng powder may have some immunomodulatory properties associated with CD3 and CD4 activity in patients with advanced gastric cancer during postoperative chemotherapy.
  • [MeSH-major] Adenocarcinoma / surgery. Immunity / drug effects. Panax. Phytotherapy. Stomach Neoplasms / surgery
  • [MeSH-minor] Aged. Antigens, CD19 / immunology. Antigens, CD3 / immunology. CD4-CD8 Ratio. Combined Modality Therapy. Female. Humans. Leukocyte Count. Lymph Node Excision. Male. Middle Aged. Postoperative Period. Prospective Studies. Receptors, IgG / immunology. Survival Analysis. T-Lymphocyte Subsets / drug effects. T-Lymphocyte Subsets / immunology

  • MedlinePlus Health Information. consumer health - Herbal Medicine.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12568276.001).
  • [ISSN] 0192-415X
  • [Journal-full-title] The American journal of Chinese medicine
  • [ISO-abbreviation] Am. J. Chin. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD19; 0 / Antigens, CD3; 0 / Receptors, IgG
  •  go-up   go-down


15. Ishii R, Takiguchi N, Oda K, Koda K, Miyazaki M: Thymidine phosphorylase expression is useful in selecting adjuvant chemotherapy for stage III gastric cancer. Int J Oncol; 2001 Oct;19(4):717-22
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thymidine phosphorylase expression is useful in selecting adjuvant chemotherapy for stage III gastric cancer.
  • To assess whether TP expression is useful for selecting adjuvant chemotherapy in advanced gastric cancer, we compared effects of oral 5'-DFUR and 5-FU and assessed correlation between drug efficacy and TP expression level.
  • When we compared prognosis in two chemotherapy groups with high TP expression, better survival was observed in 5'-DFUR than in 5-FU group (p=0.0413).
  • Especially in stage III, patients with high TP had better survival in 5'-DFUR than in 5-FU group.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Floxuridine / therapeutic use. Fluorouracil / therapeutic use. Stomach Neoplasms / enzymology. Thymidine Phosphorylase / metabolism
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Disease-Free Survival. Female. Humans. Immunoenzyme Techniques. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. FLOXURIDINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11562746.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 039LU44I5M / Floxuridine; EC 2.4.2.4 / Thymidine Phosphorylase; U3P01618RT / Fluorouracil; V1JK16Y2JP / doxifluridine
  •  go-up   go-down


16. Fujitani K, Tamura S, Kimura Y, Tsuji T, Matsuyama J, Iijima S, Imamura H, Kurokawa Y, Tsujinaka T, Furukawa H: Phase II feasibility study of adjuvant S-1 plus docetaxel for stage III gastric cancer patients after curative D2 gastrectomy (OGSG 0604). J Clin Oncol; 2009 May 20;27(15_suppl):e15567

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II feasibility study of adjuvant S-1 plus docetaxel for stage III gastric cancer patients after curative D2 gastrectomy (OGSG 0604).
  • : e15567 Background: Although an adjuvant chemotherapy with S-1 has become the standard treatment for stage II-III gastric cancer (GC) patients (pts) after curative D2 gastrectomy in Japan, the survival benefit for stage III pts obtained by S-1 is considered to be modest.
  • This phase II study evaluated the feasibility and safety of adjuvant S-1 plus docetaxel for stage III GC pts after R0 resection.
  • METHODS: Patients with curatively resected pathological stage III GC receiving D2 dissection, age 20-80 years, performance status < 1, no prior adjuvant treatment, adequate organ function, and informed consent were given S-1 (80 mg/m<sup>2</sup>/day) orally for consecutive 2 weeks plus docetaxel (40 mg/m<sup>2</sup>) intravenously on day 1, repeated every 3 weeks.
  • The treatment was started within 45 days after gastrectomy, and repeated for 4 cycles, followed by S-1 monotherapy until 1 year after surgery.
  • Study endpoints included feasibility of the 4 cycles of S-1 plus docetaxel as primary, and safety, progression free survival (PFS), and OS as secondary.
  • Planned 4 cycles of treatment were delivered to 41 out of 53 pts, with the feasibility of 77.4% (95% CI 63.8-87.7%, P<0.001).
  • Reasons for discontinuation were recurrent cancer in 1 pt, adverse events in 10, and miscellaneous in 1, respectively.
  • No treatment-related deaths occurred.
  • Although follow-up is ongoing on survival, this regimen could be a candidate of future phase III trial seeking for the optimal adjuvant chemotherapy for stage III GC pts after curative D2 gastrectomy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962326.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Oh S, Kim S, Kwon H, Kim H, Hwang I, Kang J, Lee S, Lee J, Kang W: Leptomeningeal carcinomatosis of gastric cancer: Multicenter retrospective analysis of 54 cases. J Clin Oncol; 2009 May 20;27(15_suppl):e15658

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Leptomeningeal carcinomatosis of gastric cancer: Multicenter retrospective analysis of 54 cases.
  • : e15658 Background: Leptomeningeal carcinomatosis occurs in approximately 5% of patients with cancer.
  • The most common cancers involving the leptomeninges are breast and lung cancer.
  • However, gastric adenocarcinoma has been rarely reported with leptomeningeal carcinomatosis (LMC).
  • METHODS: We analyzed 54 cases of cytological confirmed gastric LMC at 4 institutions from 1994 to 2007.
  • The majority of patients had advanced disease at the initial diagnosis of gastric cancer.
  • The clinical or pathologic TNM stages of the primary gastric cancer were IV in 38 patients (70%).
  • The median interval from the diagnosis of the primary malignancy to the diagnosis of LMC was 6.3 months (range, 0 - 73.1 months).
  • Of the initial endoscopic finding available 45 patients, Bormann type III and IV were 23 (51%) and 15 (33%) patients, respectively.
  • The intrathecal (IT) chemotherapy was administered to 36 patients - mainly with methotraxate alone (59%) or combination with ara- C/hydrocortisone (41%).
  • Median IT treatment number was 7 (range, 1-18).
  • Concomitant radiotherapy or chemotherapy was done in 25 patients and 10 patients, respectively.
  • Clinically, initial advanced stage was predictive value of poor prognosis (P=0.009).
  • And, not only IT chemotherapy but also intravenous chemotherapy had been shown improvement of survival duration (P=0.010, P=0.005, respectively).
  • CONCLUSIONS: Although gastric LMC has dismal prognosis, IT and IV chemotherapy could be help to extend survival duration of gastric LMC.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962774.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Kim JP, Yu HJ, Lee JH: Results of immunochemo-surgery for gastric carcinoma. Hepatogastroenterology; 2001 Sep-Oct;48(41):1227-30
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of immunochemo-surgery for gastric carcinoma.
  • BACKGROUND/AIMS: Although the therapeutic results of gastric cancer have markedly improved, it still remains the most common cancer death in Korea.
  • METHODOLOGY: The clinicopathologic characteristics were analyzed for 11,491 consecutive patients who underwent operation for gastric cancer at the Department of Surgery, Seoul National University Hospital from 1971 to 1997.
  • The prognostic significance of treatment modality [surgery alone, surgery + chemotherapy, surgery + immunotherapy + chemotherapy (immunochemo-surgery)] were evaluated in stage III gastric cancer.
  • The 5-year survival rates according to TNM stage were 92.9% for Ia, 84.2% for Ib, 69.3% for II, 45.8% for IIIa, 29.6% for IIIb and 9.2% for IV.
  • Regarding adjuvant treatment modality, significant survival difference was observed in stage III patients.
  • The 5-year survival rates were 44.8% for the immunochemo-surgery group, 36.8% for the surgery + chemotherapy group and 27.2% for the surgery alone group.
  • CONCLUSIONS: Curative resection, depth of invasion and lymph node metastasis were the most significant prognostic factors in gastric cancer.
  • Consequently, early detection and curative resection with radical lymph node dissection, followed by immunochemotherapy especially in patients with stage III gastric cancer should be recommended as a standard treatment principle for patients with gastric cancer.
  • [MeSH-major] Adenocarcinoma / surgery. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Picibanil / therapeutic use. Stomach Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Randomized Controlled Trials as Topic. Retrospective Studies. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11677936.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 39325-01-4 / Picibanil
  •  go-up   go-down


19. Kim JP, Lee JH, Yu HJ, Yang HK: Result of 11,946 gastric cancer treatment with immunochemosurgery. Gan To Kagaku Ryoho; 2000 May;27 Suppl 2:206-14
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Result of 11,946 gastric cancer treatment with immunochemosurgery.
  • Although the therapeutic results of gastric cancer have markedly improved, it still remains the most common of cancer deaths in Korea.
  • Annually more than 700, and all together 11,946, gastric cancer patients were surgically treated from 1970 to 1998 at Seoul National University Hospital.
  • Stage III gastric cancer is already a systemic disease, Radical surgery alone cannot cure the patient, and about 35% recurred within 2-3 years.
  • To improve the prognosis of advanced gastric cancer, systemic treatment such as immunotherapy and chemotherapy is required in the early postoperative period to kill the micrometastatic or remaining cancer cells after curative resection.
  • The clinicopathologic variables used for evaluating prognostic values were classified into patient, -tumor- and treatment-related factors.
  • The prognostic significance of treatment modality was evaluated in stage III gastric cancer.
  • Radical lymph node dissection was found to produce survival gains in patients with stage II and IIIa.
  • For postoperative adjuvant therapy, immunochemotherapy was most effective in patients with stage III.
  • Consequently, early detection and real curative resection with radical lymph node dissection, followed by immunochemotherapy (particularly in patients with stage III gastric cancer) should be recommended as a standard treatment principle for patients with gastric cancer.
  • [MeSH-major] Gastrectomy. Lymph Node Excision. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Adult. Age Factors. Female. Humans. Immunotherapy. Male. Middle Aged. Multivariate Analysis. Neoplasm Staging. Prognosis. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10895156.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] JAPAN
  • [Number-of-references] 14
  •  go-up   go-down


20. Kolh P, Honore P, Degauque C, Gielen J, Gerard P, Jacquet N: Early stage results after oesophageal resection for malignancy - colon interposition vs. gastric pull-up. Eur J Cardiothorac Surg; 2000 Sep;18(3):293-300
ORBi (University of Liege). Free full Text at ORBi .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early stage results after oesophageal resection for malignancy - colon interposition vs. gastric pull-up.
  • OBJECTIVE: The aims of our study were to determine if using the colon as a digestive transplant after oesophagectomy for cancer was associated with increased postoperative complications, and to assess the impact of preoperative radiochemotherapy on postoperative hospital outcome.
  • METHODS: From January 1990 to December 1998, 130 patients underwent oesophageal resection for malignancy.
  • Preoperatively 30 patients (eight in stage IIB, 18 in stage III, and four in stage IV) received radiochemotherapy.
  • There were 84 subtotal oesophagectomies, with anastomosis in the neck in 44 patients and at the thoracic inlet in 40, and 46 distal oesophageal resections.
  • Digestive continuity was restored with the stomach in 92 patients (age: 63.4+/-10.2 years) and the colon in 38 (age: 52.3+/-12.8 years).
  • With the exception of age (P<0.0001), there was no significant preoperative difference between gastric and colonic groups.
  • One patient (2.5%) died in the colonic graft group and ten (11%) in the gastric pull-up group (P=0.17).
  • Postoperative complications occurred in 40 patients (31%), respectively, in ten (26%) and 30 (33%) patients after colonic and gastric transplants (P=0.48), and were pulmonary insufficiency or infection in 29 patients, anastomotic fistula in six, myocardial infarction in five, recurrent nerve palsy in four, renal insufficiency in three, and cerebrovascular accident in one.
  • All fistulas occurred in the gastric pull-up group.
  • The incidence of postoperative pulmonary complications was 70% (21/30 patients) in the subgroup who received preoperative radiochemotherapy, as compared to 11% (5/44 patients) in the subgroup of comparable staging, but without preoperative treatment (P<0.001).
  • Our results suggest that preoperative neoadjuvant treatment significantly increases postoperative pulmonary complications.
  • [MeSH-major] Adenocarcinoma / surgery. Carcinoma, Squamous Cell / surgery. Colon / transplantation. Esophageal Neoplasms / surgery. Esophagus / surgery. Stomach / surgery
  • [MeSH-minor] Anastomosis, Surgical / methods. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Esophagectomy. Female. Hospital Mortality. Humans. Male. Middle Aged. Palliative Care. Reoperation. Retrospective Studies. Stomach Neoplasms / drug therapy. Stomach Neoplasms / mortality. Stomach Neoplasms / radiotherapy. Stomach Neoplasms / surgery. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10973538.001).
  • [ISSN] 1010-7940
  • [Journal-full-title] European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  • [ISO-abbreviation] Eur J Cardiothorac Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] ENGLAND
  •  go-up   go-down


21. Ennibi K, Mikdame M, Rabhi M, Jroundi I, Benkirane A, Chaari J, Toloune F: [Primary gastric lymphoma: a retrospective series of 35 cases]. Tunis Med; 2008 May;86(5):457-62
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary gastric lymphoma: a retrospective series of 35 cases].
  • [Transliterated title] Le lymphome gastrique primitif (etude rétrospective d'une série de 35 patients).
  • BACKGROUND: Primary gastric non Hodgkin's lymphoma (PGNHL) is the most common site of extranodal malignant lymphoma.
  • It is a rare subtype of malignancy, for which no consensus exists about treatment.
  • 20 (57.1%) were in stage IE/IIE1.
  • 15 patients (42.8%) were in stage IIE2,IIIE,IVE.
  • These patients were treated with primary surgery with or without chemotherapy (11; 31.4%); primary chemotherapy (CT) alone with surgery in one patient (21; 60%) and three patients with gastric MALT lymphoma were treated by Helicobacter pylori eradication.
  • The 5-year survival rates for stage I/IIE1 and IIE2/III/IV patients were 80%, 53.3% respectively (p < 0.144).
  • Of the 11 primary surgical groups with or without chemotherapy, the 5 year survival rate is 90.9%.
  • Of the 3 patients with low-grade mucosa-associated lymphoid tissue (MALT) lymphoma with only oral anti-Helicobacter pylori regimen remained disease-free after a median follow-up of two years.
  • CONCLUSIONS: This study suggested that primary surgical resection may be important factor predicting the long-term survival of patients with primary gastric NHL. H. pylori eradication therapy was an effective first-line treatment for patients with gastric MALT lymphoma.
  • [MeSH-major] Lymphoma, Non-Hodgkin / therapy. Stomach Neoplasms / therapy

  • Genetic Alliance. consumer health - Gastric Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19469300.001).
  • [ISSN] 0041-4131
  • [Journal-full-title] La Tunisie médicale
  • [ISO-abbreviation] Tunis Med
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Tunisia
  •  go-up   go-down


22. Akagi J, Baba H: PSK may suppress CD57(+) T cells to improve survival of advanced gastric cancer patients. Int J Clin Oncol; 2010 Apr;15(2):145-52
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PSK may suppress CD57(+) T cells to improve survival of advanced gastric cancer patients.
  • BACKGROUND: A recent report showed that oral adjuvant immunochemotherapy with protein-bound polysaccharide K (PSK) and tegafur/uracil (UFT) for stage II and III colorectal cancer improves overall survival compared with UFT alone.
  • METHODS: We investigated the mechanisms by which PSK influences immunological parameters such as Th1 cells (IFN-gamma-positive CD4(+) T cells), Th2 cells (IL-4-positive CD4(+) T cells), Th1/Th2 ratio, NKT cells (CD56(+) T cells and CD57(+) T cells), NK cells, and CD25(+)CD4(+) T cells in stage III gastric cancer patients.
  • Patients were randomly assigned to receive either 3 g PSK plus 300 mg UFT (PSK group) or 300 mg UFT alone (control) orally each day for at least 1 year following their operation.
  • RESULTS: Twenty-one registered patients with stage III gastric cancer were analyzed.
  • When all patients were analyzed, patients with increased proportion (>18%) of CD57(+) T cells showed worse survival than those with lower (< or = 18%) CD57(+) T cells (3-year survival, 25.0 and 45.7%, respectively; P = 0.046), consistent with our previous report that high CD57(+) is an indicator of poor prognosis in patients with advanced gastric cancer.
  • CONCLUSION: The present findings suggest that PSK improves overall survival of stage III gastric cancer patients partly by inhibiting CD57(+) T cells, a proven poor prognostic factor in advanced gastric cancer.
  • [MeSH-major] Antigens, CD57 / analysis. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Stomach Neoplasms / drug therapy. T-Lymphocyte Subsets / drug effects
  • [MeSH-minor] Aged. Chemotherapy, Adjuvant. Chi-Square Distribution. Drug Combinations. Female. Fungal Proteins / administration & dosage. Gastrectomy. Humans. Kaplan-Meier Estimate. Lymph Node Excision. Male. Middle Aged. Neoplasm Staging. Polysaccharides / administration & dosage. Tegafur / administration & dosage. Time Factors. Treatment Outcome. Uracil / administration & dosage

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 1992 Apr 1;79(7):1746-53 [1373086.001]
  • [Cites] J Immunol. 2000 Jan 1;164(1):183-90 [10605010.001]
  • [Cites] Clin Exp Immunol. 1995 Oct;102(1):159-66 [7554383.001]
  • [Cites] Cancer Treat Rev. 1984 Jun;11(2):131-55 [6238674.001]
  • [Cites] Arthritis Rheum. 1993 May;36(5):608-12 [7683880.001]
  • [Cites] Int J Clin Oncol. 2008 Dec;13(6):528-35 [19093181.001]
  • [Cites] Clin Cancer Res. 2003 Oct 1;9(12):4404-8 [14555512.001]
  • [Cites] J Cancer Res Clin Oncol. 1992;118(8):609-14 [1355484.001]
  • [Cites] Clin Exp Immunol. 1994 Sep;97(3):522-7 [7521809.001]
  • [Cites] Dis Colon Rectum. 1992 Feb;35(2):123-30 [1735313.001]
  • [Cites] Clin Exp Immunol. 1998 Feb;111(2):345-52 [9486402.001]
  • [Cites] Transplantation. 1985 Jan;39(1):25-9 [3880961.001]
  • [Cites] J Exp Med. 2001 Jun 4;193(11):F41-6 [11390442.001]
  • [Cites] Eur J Immunol. 1994 Nov;24(11):2882-8 [7525310.001]
  • [Cites] Immunol Lett. 2004 Feb 15;91(2-3):229-38 [15019294.001]
  • [Cites] Cancer Res. 1995 Dec 15;55(24):6146-51 [8521406.001]
  • [Cites] Int Immunol. 1998 Mar;10(3):311-23 [9576619.001]
  • [Cites] Br J Haematol. 1998 Mar;100(3):469-77 [9504628.001]
  • [Cites] J Exp Med. 2000 Jul 17;192(2):303-10 [10899917.001]
  • [Cites] Cancer Res. 2003 Aug 1;63(15):4516-20 [12907625.001]
  • [Cites] Clin Exp Immunol. 1990 Oct;82(1):145-50 [1698579.001]
  • [Cites] Blood. 1994 Jan 15;83(2):587-95 [7506956.001]
  • [Cites] J Immunol. 2007 Apr 15;178(8):5010-7 [17404283.001]
  • [Cites] Br J Cancer. 2004 Mar 8;90(5):1003-10 [14997197.001]
  • [Cites] J Exp Med. 1995 Feb 1;181(2):775-9 [7836930.001]
  • [Cites] Cancer Immunol Immunother. 2007 Jun;56(6):905-11 [17106715.001]
  • [Cites] Cell. 2000 May 26;101(5):455-8 [10850488.001]
  • [Cites] J Clin Oncol. 2006 Dec 1;24(34):5350-7 [17135637.001]
  • [Cites] Adv Cancer Res. 2008;101:277-348 [19055947.001]
  • [Cites] Int J Cancer. 2002 Apr 20;98(6):864-72 [11948464.001]
  • [Cites] J Surg Oncol. 1994 Mar;55(3):179-85 [8176929.001]
  • [Cites] J Clin Pathol. 1994 Jun;47(6):505-7 [8063930.001]
  • [Cites] Anticancer Res. 2002 Nov-Dec;22(6B):3679-83 [12552976.001]
  • [Cites] Oncol Rep. 2003 Sep-Oct;10(5):1443-8 [12883721.001]
  • [Cites] Lymphokine Res. 1990 Winter;9(4):475-83 [2090874.001]
  • [Cites] Cancer. 2003 Sep 1;98(5):1089-99 [12942579.001]
  • [Cites] J Exp Med. 1998 Jul 20;188(2):287-96 [9670041.001]
  • [Cites] Blood. 1995 Aug 15;86(4):1408-19 [7632949.001]
  • [Cites] Clin Cancer Res. 2003 Feb;9(2):606-12 [12576425.001]
  • [Cites] Blood. 1991 May 15;77(10):2237-41 [1709378.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Oct 23;98(22):12636-41 [11592984.001]
  • [Cites] Nature. 1997 Oct 16;389(6652):737-42 [9338786.001]
  • [Cites] Blood. 2001 Nov 1;98(9):2817-27 [11675356.001]
  • [Cites] Lancet. 1994 May 7;343 (8906):1122-6 [7910230.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1995 Apr-May;4(3):275-81 [7606203.001]
  • [Cites] Cancer Res. 2004 Feb 1;64(3):1171-80 [14871854.001]
  • (PMID = 20229169.001).
  • [ISSN] 1437-7772
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antigens, CD57; 0 / Drug Combinations; 0 / Fungal Proteins; 0 / Polysaccharides; 0 / UFT(R) drug; 0 / protein-bound polysaccharide K, Basidiomycetes; 1548R74NSZ / Tegafur; 56HH86ZVCT / Uracil
  •  go-up   go-down


23. Liang QL, Pan DC, Yin ZM, Liu GX, Yang Q, Xie JR, Cai LZ, Fu YW: [Clinical value of serum soluble Apo-1/Fas for predicting biological behaviors and prognosis of gastric carcinoma]. Ai Zheng; 2002 Feb;21(2):174-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical value of serum soluble Apo-1/Fas for predicting biological behaviors and prognosis of gastric carcinoma].
  • BACKGROUND & OBJECTIVE: Literatures reported that the soluble Apo-1/Fas(sApo-1/Fas) levels in serum of patients with malignant carcinoma were higher than that in normal control subject, but there were fewer studies was seldom to detect the level of sApo-1/Fas in patients with malignancy carcinoma and effect of chemotherapy; the subject is to detect the level of sApo-1/Fas in patients with gastric carcinoma and effect of chemotherapy on it, and to investigate its clinical value.
  • METHODS: Enzyme linked immunosorbent assays(ELISA) was available to detect the level of sApo-1/Fas in 42 case of patients with gastric carcinoma before and after chemotherapy, as compared with 30 case of normal control subject.
  • RESULTS: Levels of sApo-1/Fas were elevated in all subgroups of patients with gastric carcinoma as compared to the controls (P < 0.01), sApo-1/Fas was correlated with clinical stage and histological grade, and not with sex, age; the sApo-1/Fas level in stage IV was higher in comparison with stage III and II (P < 0.05-0.01), and in stage III it was higher than in stage II (P < 0.05); being lower in the well differentiated and moderately differentiated than the poorly differentiated(P < 0.05-0.01), that the sApo-1/Fas levels were remarkably reduced in complete remission or partial remission patients(P < 0.01) after chemotherapy.
  • CONCLUSION: sApo-1/Fas may play closely reflect growth and regulation in gastric carcinoma, it may be a predictor for biological behaviors and prognosis of gastric carcinoma; sApo-1/Fas may be a new target in treating gastric carcinoma.
  • [MeSH-major] Antigens, CD95 / blood. Stomach Neoplasms / blood

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12479070.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD95
  •  go-up   go-down


24. Misra S, Chaturvedi A, Misra NC: Gallbladder cancer. Curr Treat Options Gastroenterol; 2006 Apr;9(2):95-106

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gallbladder cancer.
  • Gallbladder cancer (GBC) is the most common malignancy of the biliary tract and the fifth most common gastrointestinal (GI) cancer.
  • Most GBC presents clinically as advanced disease with unfavorable prognosis and poor response to treatment.
  • Such patients are generally in an earlier stage of disease and are potentially more curable by a completion radical cholecystectomy, which is especially indicated for patients whose disease is stage pT1b or beyond.
  • Radical surgery is the mainstay of curative intent treatment for GBC.
  • When feasible, extended or radical cholecystectomy is the standard treatment for resectable GBC.
  • Patients with advanced stage III or IV disease may undergo more complex, high-risk, and morbid extended resections such as hepatopancreaticoduodenectomy.
  • Patients not fit for such major resection or found unresectable on imaging or exploration are usually offered palliative treatment.
  • This may be in the form of surgical palliation (eg, palliative bypass for gastric outlet, bowel, or biliary tract obstruction), endoscopic biliary stenting (for obstructive jaundice), or palliative chemotherapy.
  • Chemotherapy for GBC is generally used in the palliative setting.
  • Patients with advanced GBC and jaundice who undergo stenting followed by chemotherapy show response and survival rates similar to those who present without jaundice.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Semin Oncol. 2002 Dec;29(6 Suppl 20):40-5 [12577232.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Jan 1;52(1):167-75 [11777635.001]
  • [Cites] Cancer. 2005 Jan 1;103(1):111-8 [15558814.001]
  • [Cites] Am Surg. 2001 Nov;67(11):1041-7 [11730220.001]
  • [Cites] Cancer. 1998 Aug 1;83(3):423-7 [9690533.001]
  • [Cites] Eur J Surg Oncol. 2000 Mar;26(2):164-7 [10744937.001]
  • [Cites] Cancer. 2003 Oct 15;98(8):1689-700 [14534886.001]
  • [Cites] Hepatogastroenterology. 2000 Jul-Aug;47(34):948-55 [11020856.001]
  • [Cites] Ann Surg. 1996 Nov;224(5):639-46 [8916879.001]
  • [Cites] Hepatogastroenterology. 1991 Apr;38(2):170-5 [1649788.001]
  • [Cites] Br J Surg. 2001 May;88(5):675-8 [11350438.001]
  • [Cites] Invest New Drugs. 2002 Aug;20(3):351-6 [12201499.001]
  • [Cites] Semin Surg Oncol. 2000 Sep-Oct;19(2):145-55 [11126379.001]
  • [Cites] World J Surg. 2002 Jul;26(7):867-71 [11960212.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2001;8(6):518-24 [11956902.001]
  • [Cites] Lancet Oncol. 2003 Mar;4(3):167-76 [12623362.001]
  • [Cites] Cancer. 1996 Sep 15;78(6):1300-7 [8826954.001]
  • [Cites] Cancer. 2002 Oct 15;95(8):1685-95 [12365016.001]
  • [Cites] Eur J Surg Oncol. 2000 Aug;26(5):438-43 [11016462.001]
  • [Cites] Clin Cancer Res. 2001 Nov;7(11):3375-80 [11705850.001]
  • [Cites] Ann Oncol. 1998 Jun;9(6):653-6 [9681080.001]
  • [Cites] Ann Oncol. 2001 Oct;12(10):1403-6 [11762811.001]
  • [Cites] J Clin Oncol. 2005 Apr 1;23(10):2332-8 [15800324.001]
  • [Cites] Eur J Surg. 1997 Jun;163(6):419-26 [9231853.001]
  • [Cites] Chemotherapy. 2003 Jun;49(3):154-8 [12815209.001]
  • [Cites] Ann Oncol. 2002 Aug;13(8):1192-6 [12181241.001]
  • [Cites] Surg Gynecol Obstet. 1978 Dec;147(6):929-42 [362580.001]
  • [Cites] J Clin Oncol. 1996 Aug;14 (8):2311-5 [8708722.001]
  • [Cites] Ann Oncol. 2004 Mar;15(3):478-83 [14998852.001]
  • [Cites] Br J Cancer. 2004 Apr 19;90(8):1516-20 [15083178.001]
  • [Cites] World J Surg. 2000 Oct;24(10):1271-6; discussion 1277 [11071474.001]
  • [Cites] Br J Surg. 1994 Nov;81(11):1655-7 [7827897.001]
  • [Cites] CA Cancer J Clin. 2001 Nov-Dec;51(6):349-64 [11760569.001]
  • [Cites] World J Surg. 1991 May-Jun;15(3):337-43 [1853612.001]
  • [Cites] World J Surg. 2003 Mar;27(3):266-71 [12607049.001]
  • [Cites] Br J Surg. 2002 Feb;89(2):179-84 [11856130.001]
  • [Cites] Nat Rev Cancer. 2004 Sep;4(9):695-706 [15343276.001]
  • [Cites] Adv Surg. 2001;35:1-20 [11579805.001]
  • [Cites] Cancer. 1977 Apr;39(4):1425-9 [192431.001]
  • [Cites] J Gastrointest Surg. 2004 Jan;8(1):83-9; discussion 89 [14746839.001]
  • [Cites] Eur J Surg Oncol. 2005 Feb;31(1):45-52 [15642425.001]
  • [Cites] J Am Coll Surg. 2001 May;192(5):600-7 [11333097.001]
  • [Cites] World J Surg. 1995 Sep-Oct;19(5):758-63 [7571677.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Jul 15;62(4):1030-4 [15990005.001]
  • [Cites] Ann Surg. 2000 Oct;232(4):557-69 [10998654.001]
  • [Cites] Hepatogastroenterology. 1998 Jan-Feb;45(19):14-9 [9496479.001]
  • [Cites] Oncology (Williston Park). 2004 Jul;18(8):1049-59; discussion 1060, 1065-6, 1068 [15328897.001]
  • [Cites] Ann Surg. 2005 Mar;241(3):385-94 [15729060.001]
  • [Cites] Ann Oncol. 2004 Sep;15(9):1339-43 [15319238.001]
  • [Cites] Ann Surg. 1994 Mar;219(3):275-80 [8147608.001]
  • (PMID = 16539870.001).
  • [ISSN] 1092-8472
  • [Journal-full-title] Current treatment options in gastroenterology
  • [ISO-abbreviation] Curr Treat Options Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Ceelen WP, Hesse U, de Hemptinne B, Pattyn P: Hyperthermic intraperitoneal chemoperfusion in the treatment of locally advanced intra-abdominal cancer. Br J Surg; 2000 Aug;87(8):1006-15
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hyperthermic intraperitoneal chemoperfusion in the treatment of locally advanced intra-abdominal cancer.
  • BACKGROUND: Surgical treatment of intra-abdominal cancer is often followed by local recurrence.
  • In a subgroup of patients, local recurrence is the sole site of disease, reflecting biologically low-grade malignancy.
  • These patients might, therefore, benefit from local treatment.
  • Recently, debulking surgery followed by hyperthermic chemoperfusion has been proposed in the treatment of locally advanced or recurrent intra-abdominal cancer.
  • This paper reviews the rationale and assesses the currently accepted indications for and results of this novel treatment.
  • RESULTS: A growing body of experimental evidence supports the use of hyperthermia combined with chemotherapy as an adjunct to cytoreductive surgery.
  • Randomized clinical trials are available to support its use in the treatment and prevention of peritoneal carcinomatosis following resection of pathological tumour stage pT3 or pT4 gastric cancer; several other phase III trials are ongoing.
  • CONCLUSION: For a subgroup of patients with peritoneal cancer without distant disease, debulking surgery followed by hyperthermic chemoperfusion may offer a chance of cure or palliation in this otherwise untreatable condition.
  • This novel therapy should, however, be considered experimental until further results from ongoing phase III trials become available.
  • [MeSH-major] Abdominal Neoplasms / therapy. Hyperthermia, Induced / methods
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Chemotherapy, Cancer, Regional Perfusion / methods. Colorectal Neoplasms / therapy. Combined Modality Therapy / methods. Female. Humans. Mesothelioma / therapy. Neoplasm Recurrence, Local / therapy. Ovarian Neoplasms / therapy. Sarcoma / therapy. Stomach Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Br J Surg. 2001 Jan;88(1):152 [11136331.001]
  • (PMID = 10931042.001).
  • [ISSN] 0007-1323
  • [Journal-full-title] The British journal of surgery
  • [ISO-abbreviation] Br J Surg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] ENGLAND
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 105
  •  go-up   go-down


26. Fata F, Ron IG, Maluf F, Klimstra D, Kemeny N: Intra-abdominal fibrosis after systemic and intraperitoneal therapy containing fluoropyrimidines. Cancer; 2000 Jun 1;88(11):2447-51
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intra-abdominal fibrosis after systemic and intraperitoneal therapy containing fluoropyrimidines.
  • The IP administration of floxuridine (FUDR) is an effective and minimally toxic treatment for patients with metastases to the peritoneum.
  • An increasing number of patients with colorectal, gastric, or ovarian carcinoma are treated with IP chemotherapy.
  • RESULTS: Two patients with Stage III colon adenocarcinoma received postoperative adjuvant 5-fluorouracil and levamisole.
  • CONCLUSIONS: IP FUDR and leucovorin therapy can be associated with diffuse IP fibrosis, which in this study caused an intra-abdominal mass that was indistinguishable from recurrent malignancy in one patient and encasement of the bowel in the other.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Colorectal Neoplasms / drug therapy. Infusions, Parenteral / adverse effects. Peritoneum / drug effects

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • Hazardous Substances Data Bank. FLOXURIDINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 American Cancer Society.
  • (PMID = 10861419.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 039LU44I5M / Floxuridine; Q573I9DVLP / Leucovorin
  •  go-up   go-down


27. Kono K, Kawaguchi Y, Mizukami Y, Mimura K, Sugai H, Akaike H, Fujii H: Protein-bound polysaccharide K partially prevents apoptosis of circulating T cells induced by anti-cancer drug S-1 in patients with gastric cancer. Oncology; 2008;74(3-4):143-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Protein-bound polysaccharide K partially prevents apoptosis of circulating T cells induced by anti-cancer drug S-1 in patients with gastric cancer.
  • BACKGROUND AND METHODS: It has been shown that T-cell dysfunction, including apoptosis of peripheral blood T cells, commonly occurs in patients receiving chemotherapy.
  • In order to evaluate whether concomitant administration of the oral biological response modifier protein-bound polysaccharide K (PSK) could induce anti-apoptotic effects in patients treated with the anti-cancer drug, S-1, peripheral blood T cells were analyzed for induction of apoptosis, caspase-3 activities and expression of proapoptotic protein Bax and anti-apoptotic protein Bcl-2 in patients with curatively resected stage III gastric cancer, who were randomly assigned to postoperative adjuvant therapy with S-1 alone (n = 10) or S-1 combined with PSK (n = 10).
  • RESULTS: T-cell apoptosis 5 weeks after adjuvant therapy was significantly higher in the S-1 group (24.1 +/- 5.0%) than in the S-1 + PSK group (19.1 +/- 3.9%).
  • [MeSH-major] Antibiotics, Antineoplastic / therapeutic use. Antimetabolites, Antineoplastic / therapeutic use. Apoptosis / drug effects. Oxonic Acid / therapeutic use. Proteoglycans / therapeutic use. Stomach Neoplasms / drug therapy. T-Lymphocytes / drug effects. Tegafur / therapeutic use
  • [MeSH-minor] Aged. Caspases / metabolism. Chemotherapy, Adjuvant. Drug Combinations. Drug Therapy, Combination. Female. Flow Cytometry. Humans. Male. Proto-Oncogene Proteins c-bcl-2 / metabolism. bcl-2-Associated X Protein / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 S. Karger AG, Basel.
  • (PMID = 18708731.001).
  • [ISSN] 1423-0232
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antimetabolites, Antineoplastic; 0 / Drug Combinations; 0 / Proteoglycans; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / bcl-2-Associated X Protein; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; 66455-27-4 / krestin; EC 3.4.22.- / Caspases
  •  go-up   go-down






Advertisement